Skip to content
Wenlo
Sign in
← Markets

Supernus Pharmaceuticals, Inc.

Jonathan Rubin (SVP, Chief Medical Officer) reports SUPN insider transactions

4SUPNFiled Nov 4, 2026, 11:31 AM ET· Period Nov 2, 2026

About this filing

Supernus Pharmaceuticals, Inc. (SUPN) filed Form 4 (insider transaction) with the SEC on Nov 4, 2026. Form 4 reports a company insider’s trades in the company’s shares.

View original filing on SEC.gov (opens SEC EDGAR)

Key facts

Insider
Jonathan Rubin · SVP, Chief Medical Officer
DateTransactionSharesPriceValueHeld afterOwnership
Nov 2, 2026J · otherFootnotes F1−13,979$0.00$0.000Direct
Nov 2, 2026J · otherEmployee Stock Option (Right to Buy)Footnotes F2, F3−15,000$0.00$0.000Direct
Nov 2, 2026J · otherEmployee Stock Option (Right to Buy)Footnotes F2, F4−25,000$0.00$0.000Direct
Nov 2, 2026J · otherEmployee Stock Option (Right to Buy)Footnotes F2, F5−25,000$0.00$0.000Direct
Nov 2, 2026J · otherEmployee Stock Option (Right to Buy)Footnotes F2, F6−20,000$0.00$0.000Direct
Nov 2, 2026J · otherEmployee Stock Option (Right to Buy)Footnotes F2, F7−25,000$0.00$0.000Direct
Nov 2, 2026J · otherEmployee Stock Option (Right to Buy)Footnotes F2, F8−20,000$0.00$0.000Direct
Nov 2, 2026J · otherEmployee Stock Option (Right to Buy)Footnotes F2, F9−13,500$0.00$0.000Direct
Nov 2, 2026J · otherRestricted Stock UnitFootnotes F2, F10−70,000$0.00$0.000Direct
Nov 2, 2026J · otherRestricted Stock UnitFootnotes F11, F2, F12−3,000$0.00$0.000Direct
Nov 2, 2026J · otherRestricted Stock UnitFootnotes F11, F2, F13−3,375$0.00$0.000Direct
Nov 2, 2026J · otherRestricted Stock UnitFootnotes F11, F2, F14−2,500$0.00$0.000Direct
Nov 2, 2026J · otherRestricted Stock UnitFootnotes F11, F2, F15−1,250$0.00$0.000Direct
Nov 2, 2026J · otherPerformance Share UnitFootnotes F16, F2, F17−4,250$0.00$0.000Direct
Nov 2, 2026J · otherPerformance Share UnitFootnotes F16, F2, F18−3,500$0.00$0.000Direct
Footnotes
  1. F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/26, Artemis Merger Sub Inc. merged with and into Supernus Pharmaceuticals, with Supernus Pharmaceuticals surviving as a wholly-owned subsidiary of Indivior. At the effective time, each outstanding share of Supernus Pharmaceuticals common stock was cancelled and automatically converted into the right to receive 1.5401 shares of Indivior common stock. In connection with the merger, Indivior changed its name to "Supernus, Inc." The reporting person's shares of Supernus Pharmaceuticals common stock were disposed of, and the shares of Supernus, Inc. common stock received in exchange were acquired, pursuant to the merger. The reporting person received no cash consideration other than cash in lieu of a fractional share.
  2. F2 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
  3. F3 The options vest in four equal installments beginning February 21, 2021.
  4. F4 The option vests in four equal annual installments beginning on February 19, 2022.
  5. F5 The option vests in four equal annual installments beginning on February 22, 2023.
  6. F6 The option vests in four equal annual installments beginning on February 23, 2024.
  7. F7 The option vests in four equal annual installments beginning on February 22, 2025.
  8. F8 The option vests in four equal annual installments beginning on February 19, 2026.
  9. F9 The option vests in four equal annual installments beginning on February 18, 2027.
  10. F10 These restricted stock units ("RSUs") are settled in common stock upon vesting, which occurs in four installments. 50% of the RSUs vest upon the closing of the merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (the "Closing"). 15% of the RSUs vest upon the one-year anniversary of the Closing. 15% of the RSUs vest upon the two-year anniversary of the Closing. 20% of the RSUs vest upon the three-year anniversary of the Closing.
  11. F11 Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
  12. F12 These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 18, 2027.
  13. F13 These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026.
  14. F14 These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025.
  15. F15 These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.
  16. F16 Each performance share unit represents the right to receive one share of Supernus common stock upon vesting.
  17. F17 On February 19, 2025, the Reporting Person was awarded Performance Share Units with individual performance objectives and a defined performance period established on May 3, 2025.
  18. F18 On February 18, 2026, the Reporting Person was awarded Performance Share Units with individual performance objectives and a defined performance period established on July 15, 2026.

More SUPN filings

Not investment advice. Summaries can contain errors; the SEC filing is the official record.